Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Priya Nigam

BofA Downgrades CureVac On Limited 2022 Prospects

There is limited upside from CureVac BV’s (NASDAQ:CVAC) COVID-19 vaccine and there are few catalysts from the rest of the company’s pipeline in 2022, according to BofA Securities.

The CureVac Analyst: Geoff Meacham downgraded the rating for CureVac from Neutral to Underperform, while reducing the price target from $55 to $20.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.